Liquidia Technologies Inc (LQDA) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.

Total Cash From Operating Activities Chart for Liquidia Technologies Inc

Liquidia Technologies Inc (LQDA) operating cash flow for FY2025 was USD -35.7M. Liquidia Technologies Inc's operating cash flow moved from USD -13.9M in 2016 to USD -35.7M in 2025 over 9 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$3.82B
Implied Share Price
$42.65
Enterprise Value
$5.97B
Revenue (TTM)
$450.91M
EBITDA
$169.77M
Profit Margin
30.74%
Trailing P/E
30.68
Forward P/E
10.58
Price/Book (MRQ)
31.12
Price/Sales (TTM)
8.47
EV/EBITDA
33.58
EV/Revenue
13.24
Dividend Yield
—
Book Value
$2.19
Free Cash Flow (FY2025)
-$40.02M
Free Cash Flow Yield
-1.05%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.